Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

Benalish Jun. 28 at 1:07 AM

$SNSE Holding this one for now. Cash of $30 per share on the books and low float. Looks like a cup and handle on the daily. Very low volume though; so who knows for sure.

0 · Reply

Love_To_Learn Jun. 23 at 2:10 PM

$AKBA ! $WHLR $SNSE

0 · Reply

Benalish Jun. 19 at 4:30 AM

$SNSE Has about $30 per share in cash on the books. Float seems like there's 10 shares outstanding and no shares available for shorting. Interesting.

2 · Reply

Love_To_Learn Jun. 18 at 8:58 PM

$WHLR well done had to split u 3 $SNSE $AKBA as posted early !

0 · Reply

FORTHELOVEOF Jun. 18 at 4:58 PM

$SNSE 👀

0 · Reply

FloatSN4TCH3R Jun. 18 at 4:16 PM

$SNSE

0 · Reply

PenkeTrading Jun. 18 at 2:57 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Sensei Biotherapeutics Inc. Is that bullish or bearish? $SNSE #RsiOverbought #NASDAQ

0 · Reply

TwongStocks Jun. 17 at 8:17 PM

Today's reverse split results. $RAPT 1 for 8 Previous close $1.03, $8.24 split-adjusted Today's close $7.84 🔴Down 4.85% $SNSE 1 for 20 Previous close $0.3260, $6.52 split-adjusted Today's close $6.55 🟢Up 0.46% $FGEN 1 for 25 Previous close $0.2661, $6.6525 split-adjusted Today's close $5.88 🔴Down 11.61%

0 · Reply

tradingcalendar Jun. 17 at 1:12 PM

$FGEN 1-for-25 reverse split Shares outstanding reduced to 4.0M from 101.1M $RAPT 1-for-8 reverse split Shares outstanding reduced to 16.5M from 132.3M $SNSE 1-for-20 reverse split Share float reduced to around 830K from 16.6M

0 · Reply

TwongStocks Jun. 17 at 11:08 AM

$RAPT $SNSE $FGEN Reverse splits today. All three will resume trading at 9:00am ET.

0 · Reply

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 3 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 5 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 6 months ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 8 months ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 8 months ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 9 months ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 11 months ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 1 year ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 7, 2023, 5:15 PM EST - 2 years ago

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

Mar 6, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 21, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

Feb 16, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Feb 14, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

Feb 6, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

Jan 5, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

Benalish Jun. 28 at 1:07 AM

$SNSE Holding this one for now. Cash of $30 per share on the books and low float. Looks like a cup and handle on the daily. Very low volume though; so who knows for sure.

0 · Reply

Love_To_Learn Jun. 23 at 2:10 PM

$AKBA ! $WHLR $SNSE

0 · Reply

Benalish Jun. 19 at 4:30 AM

$SNSE Has about $30 per share in cash on the books. Float seems like there's 10 shares outstanding and no shares available for shorting. Interesting.

2 · Reply

Love_To_Learn Jun. 18 at 8:58 PM

$WHLR well done had to split u 3 $SNSE $AKBA as posted early !

0 · Reply

FORTHELOVEOF Jun. 18 at 4:58 PM

$SNSE 👀

0 · Reply

FloatSN4TCH3R Jun. 18 at 4:16 PM

$SNSE

0 · Reply

PenkeTrading Jun. 18 at 2:57 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Sensei Biotherapeutics Inc. Is that bullish or bearish? $SNSE #RsiOverbought #NASDAQ

0 · Reply

TwongStocks Jun. 17 at 8:17 PM

0 · Reply

tradingcalendar Jun. 17 at 1:12 PM

0 · Reply

TwongStocks Jun. 17 at 11:08 AM

$RAPT $SNSE $FGEN Reverse splits today. All three will resume trading at 9:00am ET.

0 · Reply

chonkybottomfeeder Jun. 17 at 8:16 AM

$SNSE 4.50😛

0 · Reply

makedatbread88 Jun. 16 at 9:26 PM

$SNSE becomes a 1.3M low float tomorrow, watching

0 · Reply

TwongStocks Jun. 16 at 9:19 PM

For Tuesday, I am tracking three reverse splits on NASDAQ. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Tuesday morning. $RAPT 1 for 8. Will reduce outstanding shares from approx 132.3m to approx 16.5m. $SNSE 1 for 20. Will reduce outstanding shares from approx 25.2m to approx 1.3m. $FGEN 1 for 25. Will reduce outstanding shares from approx 101.1m to approx 4m.

1 · Reply

Whitefaced Jun. 16 at 2:09 PM

$SNSE Sensei Biotherapeutics' balance sheet indicates a strong financial position with a low debt-to-equity ratio and a healthy cash position. The company has a substantial amount of cash, cash equivalents, and marketable securities, while maintaining minimal debt. This suggests a solid foundation for continued operations and potential growth, particularly in research and development.

0 · Reply

TwongStocks Jun. 13 at 5:30 PM

$SNSE NASDAQ Equity Corporate Actions Alert # 2025 - 312 Information Regarding the Reverse Stock Split and CUSIP Number Change for Sensei Biotherapeutics, Inc. (SNSE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-312 Sensei Biotherapeutics, Inc. (SNSE) will effect a one-for-twenty (1-20) reverse split of its Common Stock. The reverse stock split will become effective on Tuesday, June 17, 2025. In conjunction with the reverse split, the CUSIP number will change to 81728A207.

0 · Reply

Whitefaced Jun. 13 at 3:20 PM

$SNSE .....and the buying stops

0 · Reply

Whitefaced Jun. 9 at 3:20 PM

$SNSE in at .36

0 · Reply